Shots:
- Xbrane Biopharma will reclaim full rights of BIIB801 from Biogen after the termination of their commercialization and license agreement. BIIB801 is a biosimilar version of Cimzia (certolizumab pegol), under non-clinical development
- The agreement was signed b/w Xbrane & Biogen in Feb 2022, under which Xbrane received a non-refundable $8M upfront. It has been terminated due to Biogen’s strategic review and Xbrane will get full rights to the program
- Xbrane has begun an out-licensing process to find a new development & commercialization partner & has received significant interest for the same. The production has been scaled up with Xbrane’s contract manufacturer, with clinical material production in 2024, enabling clinical trials in 2025
Ref: Xbrane Biopharma | Image: Xbrane Biopharma| Press Release
Related News:- Celltrion’s Steqeyma (Biosimilar, Stelara) Receives the Health Canada’s Approval to Treat Various Chronic Inflammatory Conditions
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
